Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 01:20PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director

Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Cerevel with us. Just quickly before we get started, I need to make a disclosure statement.

Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. With that, really happy to have Tony Coles, who is the CEO at Cerevel. Tony, I'm going to let you make some opening comments, and then we can jump into it.

N. Anthony Coles - Cerevel Therapeutics Holdings, Inc. - Executive Chairman & CEO

Okay. Good. Well, good morning, Matthew. Thank you for having us. I will be making some forward-looking statements. So that's our disclaimer at the front. Cerevel is a company that was formed 4 years ago as a result of the spinout of the Pfizer Neuroscience assets, which anyone, who

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot